Salvatore Chirumbolo- Department of Medicine, University Laboratories for Medical Research (LURM)-Medicine D, University of Verona, Verona, Italy
A commentary on
Research on the immunosuppressive activity of ingredients contained in sunscreens
by: Frikeche, J., Couteau, C., Roussakis, C., and Coiffard, L. J. (2015). Arch. Dermatol. Res. 307, 211–218. doi: 10.1007/s00403-014-1528-9
A recent paper showed that bisabolol contained in cosmetics drastically dampened peripheral blood lymphocyte proliferation induced by phytohemoagglutinin (PHA) and enhanced the production of tumor growth factor-beta 1 (TGF-β1) on NCTC 2544 keratinocytes, although it did not change the activity of monocytes and dendritic cells (Frikeche et al., 2015). The authors showed that some organic molecules present in sunscreens impaired DC maturation, or inhibited lymphocyte proliferation as well as increased of TGF-β1 in the cell environment. Alpha-bisabolol [6-methyl-2-(4-methylcycloex-3-en-1-yl)hept-5-en-2-ol] is a sesquiterpene alcohol, present in different isomers (Figure 1) that has been described since many years as a promising anti-tumoral compound (da Silva et al., 2010; Seki et al., 2011) It reduces mammary tumor mass in mice and promotes the natural killer (NK) cells response (Costarelli et al., 2010). Alpha-bisabolol is present in Matricaria chamomilla L. essential oils and a potent pro-apoptotic molecule (Cavalieri et al., 2011). The myth of treating cancer with chamomile extracts would find unexpected support, as this plant contains flavonoids, as apigenin-7-O-glucoside and other phytochemicals, which act as anti-proliferative and pro-apoptotic molecules, (Srivastava and Gupta, 2007). Frikeche et al. showed that bisabolol behaves as a potent immuno-suppressant, an evidence that should raise fundamental issues about the role of plant-derived molecules on the tumor microenvironment, besides their direct effect on malignant cells (Frikeche et al., 2015).
Figure 1. Alpha-bisabolol different isomers and farnesol, a possible catabolyte.
Darra et al., reported that the anti-neoplastic action exerted by α-bisabolol, derives fundamentally by its ability in inducing mitochondria-mediated apoptosis in cancer cells (Darra et al., 2007, 2008; Cavalieri et al., 2009). In particular, α-bisabolol is preferentially incorporated into malignant cells through lipid rafts and directly interacts with Bid protein (Darra et al., 2008). This mechanism, which may account for the reported anti-tumoral effect, has never been assessed in vivo and particularly Darra's in vitro evidence did not include the role of immune cells in the tumor microenvironment during α-bisabolol treatment. Promising results showed that α-bisabolol is active against primary acute leukemia cells, in synergism with tyrosine inhibitors, suggesting that its main target is the hematopoietic cell (Cavalieri et al., 2011; Bonifacio et al., 2012). Frikeche et al. would suggest that the immunosuppressive action performed by α-bisabolol on lymphocytes may have dramatic consequences on tumor development (Frikeche et al., 2015). Yet, some concern is about α-bisabolol and lipid rafts. Actually, gamma-delta phenotype T cells (TCR-γδ cells), increase lipid rafts when activated by involving membrane cholesterol (Kabouridis et al., 2000; Mahammad et al., 2010; Cheng et al., 2013). Due to its preferential entry through lipid rafts, α-bisabolol may induce apoptosis in activated T cells, while simultaneously switches off lymphocyte activation (Frikeche et al., 2015). Alpha-bisabolol tropism for immune cells may have fundamental effects on tumor immune microenvironment, probably by impairing T-cell activation and lymphocyte switching and promoting cancer editing, causing evasion from inflammation and generating immune tolerance (Vinay et al., 2015). Immune suppression in the tumor microenvironment is fundamentally mediated by CD4+CD25+FoxP3+ regulatory T cells (Tregs), as the major mechanism of tumor immune escape, a crucial hurdle for tumor immunotherapy (Jacobs et al., 2012). Bisabolol enhances TGF-β in in vitro cultured keratinocytes (Frikeche et al., 2015) and the cytokine is necessary for the progression of tumors such as hepatocellular carcinoma, acting by inducing Tregs polarization (Shen et al., 2015). In melanoma models, cancer cells induce immune escape and suppression by up-regulating CD4+CD25+FoxP3+ regulatory T cells, through TGF-β expression (Baumgartner et al., 2007). If α-bisabolol is able to increase TGF-β release, its chemopreventive potential might appear therefore quite controversial. At least apparently, α-bisabolol might induce immune suppression and tolerance by increasing the release of cytokines promoting cancer editing. Furthermore, α-bisabolol does not affect the ability of dendritic cells (DCs) to produce IL-12p70 (Johansson et al., 2011; Frikeche et al., 2015). DCs produce IL-12p70 after engulfment of apoptotic lymphocytes and this mechanism should induce immune tolerance in the absence of lymphocyte activation (Johansson et al., 2011). Furthermore, TCR-γδ cells are able to recognize several unknown antigens on tumor cells. Some metabolites of the mevalonate pathway, among which is farnesol, a possible catabolyte of α-bisabolol (Dewick, 2002), should act as tumor ligands, which can activate TCR-γδ cells (Gober et al., 2003). The role of TCR-γδ cells in tumors should appear encouraging (Hannani et al., 2012; Marquez-Medina et al., 2012), but these cells have also an immunosuppressive role when induced by TGF-β1 (Gu et al., 2014). Critical points to be addressed regards therefore the role of this sesquiterpene alcohol on immune regulation and hence on the immune competence in fighting cancer. This closely depends on the immune context where malignant cells are developing, besides to the bioavailability of α-bisabolol in situ.
Despite its promising activity as an anti-tumor molecule, α-bisabolol does not possess so different features respect to the widest family of plant-derived anti-inflammatory and chemopreventive polyphenols (Chirumbolo, 2010). The ability to induce cell apoptosis is shared with several other plant derived compounds, such as quercetin (Primikyri et al., 2014), genistein (Choi et al., 2007), apigenin (Papachristou et al., 2013), catechins (Yoon et al., 2014), resveratrol (Wang et al., 2011) and many others, for which these few examples are reported. The pro-apoptosis action should be interpreted at the light of the stress response mechanism activated by cells, a property shared by any plant-derived polyphenol, representing a general hallmark of these molecules (Fresco et al., 2010). Tumor cells have critically different patterns of stress response and they rapidly activate apoptosis pathway when stimulated by damage or stress signals, whose burden is particularly difficult to address. In this context a major role is played by endoplasmic reticulum stress (ER stress) and the unfolding protein response (UPR), besides to mitochondria (Maurel et al., 2015). While these mechanisms shed a light on the cellular impact of plant phytochemicals, their role on the cancer immune micro-environment is yet far to be fully understood. In vitro research usually neglected this issue, as most of investigations based on cell lines obviously never consider the immune microenvironment existing in the in vivo situation. In this perspective, the recent article by Frikeche et al., raises some criticism about the actual role of α-bisabolol as a real, promising chemopreventive molecule.
Alpha bisabolol might affect mitochondrial permeability transition also in non cancer cells (Leanza et al., 2013, 2014) and recent reports showed a massive death of endothelial cells by apoptosis induced from 5.0 μM α-bisabolol (Magnelli et al., 2010), a dose about 10-times lower than the one used to BCR-ABL cell viability in primary acute leukemia (Bonifacio et al., 2012).
As with other phytochemicals, the role of α-bisabolol on cancer therapy should be expanded in future debates, while any further proposals to investigate this organic compound on in vitro cancer lines, such as MiaPaCa, should be considered with caution.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
A particular acknowledgment to Dr Elena Darra, for her precious technical suggestions to this Commentary.
References
Baumgartner, J., Wilson, C., Palmer, B., Richter, D., Banerjee, A., and McCarter, M. (2007). Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J. Surg. Res. 141, 72–77. doi: 10.1016/j.jss.2007.03.053
Bonifacio, M., Rigo, A., Guardalben, E., Bergamini, C., Cavalieri, E., Fato, R., et al. (2012). α-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. PLoS ONE 7:e46674. doi: 10.1371/journal.pone.0046674
Cavalieri, E., Bergamini, C., Mariotto, S., Leoni, S., Perbellini, L., Darra, E., et al. (2009). Involvement of mitochondrial permeability transition pore opening in alpha-bisabolol induced apoptosis. FEBS J. 276, 3990–4000. doi: 10.1111/j.1742-4658.2009.07108.x
Cavalieri, E., Rigo, A., Bonifacio, M., Carcereri de Prati, A., Guardalben, E., Bergamini, C., et al. (2011). Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells. J. Transl. Med. 9:45. doi: 10.1186/1479-5876-9-45
Cheng, H. Y., Wu, R., Gebre, A. K., Hanna, R. N., Smith, D. J., Parks, J. S., et al. (2013). Increased cholesterol content in gammadelta (γδ) T lymphocytes differentially regulates their activation. PLoS ONE 8:e63746. doi: 10.1371/journal.pone.0063746
Chirumbolo, S. (2010). The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm. Allergy Drug Targets 9, 263–285. doi: 10.2174/187152810793358741
Choi, E. J., Kim, T., and Lee, M. S. (2007). Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci. 80, 1403–1408. doi: 10.1016/j.lfs.2006.12.031
Costarelli, L., Malavolta, M., Giacconi, R., Cipriano, C., Gasparini, N., Tesei, S., et al. (2010). In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. Oncol. Res. 18, 409–418. doi: 10.3727/096504010X12671222663557
Darra, E., Abdel-Azeim, S., Manara, A., Shoji, K., Maréchal, J. D., Mariotto, S., et al. (2008). Insight into the apoptosis-inducing action of alpha-bisabolol towards malignant tumor cells: involvement of lipid rafts and Bid. Arch. Biochem. Biophys. 476, 113–123. doi: 10.1016/j.abb.2008.02.004
Darra, E., Lenaz, G., Cavalieri, E., Fato, R., Mariotto, S., Bergamini, C., et al. (2007). Alpha-bisabolol: unexpected plant-derived weapon in the struggle against tumour survival? Ital. J. Biochem. 56, 323–328.
da Silva, A. P., Martini, M. V., de Oliveira, C. M., Cunha, S., de Carvalho, J. E., Ruiz, A. L., et al. (2010). Antitumor activity of (-)-alpha-bisabolol-based thiosemicarbazones against human tumor cell lines. Eur. J. Med. Chem. 45, 2987–2993. doi: 10.1016/j.ejmech.2010.03.026
Dewick, P. M. (2002). The biosynthesis of C5-C25 terpenoid compounds. Nat. Prod. Rep. 19, 181–222. doi: 10.1039/b002685i
Fresco, P., Borges, F., Marques, M. P., and Diniz, C. (2010). The anticancer properties of dietary polyphenols and its relation with apoptosis. Curr. Pharm. Des. 16, 114–134. doi: 10.2174/138161210789941856
Frikeche, J., Couteau, C., Roussakis, C., and Coiffard, L. J. (2015). Research on the immunosuppressive activity of ingredients contained in sunscreens. Arch. Dermatol. Res. 307, 211–218. doi: 10.1007/s00403-014-1528-9
Gober, H. J., Kistowska, M., Angman, L., Jenö P., Mori, L., and De Libero, G. (2003). Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163–168. doi: 10.1084/jem.20021500
Gu, Y., Hu, Y., Hu, K., Liao, W., Zheng, F., Yu, X., et al. (2014). Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells. J. Immunol. Methods 402, 82–87. doi: 10.1016/j.jim.2013.11.009
Hannani, D., Ma, Y., Yamazaki, T., Déchanet-Merville, J., Kroemer, G., and Zitvogel, L. (2012). Harnessing γδT cells in anticancer immunotherapy. Trends Immunol. 33, 199–206. doi: 10.1016/j.it.2012.01.006
Jacobs, J. F., Nierkens, S., Figdor, C. G., de Vries, I. J., and Adema, G. J. (2012). Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 13, e32–42. doi: 10.1016/S1470-2045(11)70155-3
Johansson, U., Walther-Jallow, L., Hofmann, A., and Spetz, A. L. (2011). Dendritic cells are able to produce IL-12p70 after uptake of apoptotic cells. Immunobiology 216, 251–255. doi: 10.1016/j.imbio.2010.04.003
Kabouridis, P. S., Janzen, J., Magee, A. L., and Ley, S. C. (2000). Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur. J. Immunol. 30, 954–963. doi: 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.0.CO;2-Y
Leanza, L., Biasutto, L., Managò A., Gulbins, E., Zoratti, M., and Szabò, I. (2013). Intracellular ion channels and cancer. Front. Physiol. 4:227. doi: 10.3389/fphys.2013.00227
Leanza, L., Zoratti, M., Gulbins, E., and Szabo, I. (2014). Mitochondrial ion channels as oncological targets. Oncogene 33, 5569–5581. doi: 10.1038/onc.2013.578
Magnelli, L., Caldini, R., Schiavone, N., Suzuki, H., and Chevanne, M. (2010). Differentiating and apoptotic dose-dependent effects in (-)-alpha-bisabolol-treated human endothelial cells. J. Nat. Prod. 73, 523–526. doi: 10.1021/np9003933
Mahammad, S., Dinic, J., Adler, J., and Parmryd, I. (2010). Limited cholesterol depletion causes aggregation of plasma membrane lipid rafts inducing T cell activation. Biochim. Biophys. Acta 1801, 625–634. doi: 10.1016/j.bbalip.2010.02.003
Marquez-Medina, D., Salla-Fortuny, J., and Salud-Salvia, A. (2012). Role of gamma-delta T-cells in cancer: another opening door to immunotherapy. Clin. Transl. Oncol. 14, 891–895. doi: 10.1007/s12094-012-0935-7
Maurel, M., McGrath, E. P., Mnich, K., Healy, S., Chevet, E., and Samali, A. (2015). Controlling the unfolded protein response-mediated life and death decisions in cancer. Semin. Cancer Biol. doi: 10.1016/j.semcancer.2015.03.003. [Epub ahead of print].
Papachristou, F., Chatzaki, E., Petrou, A., Kougioumtzi, I., Katsikogiannis, N., Papalambros, A., et al. (2013). Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity. Chin. Med. 8:9. doi: 10.1186/1749-8546-8-9
Primikyri, A., Chatziathanasiadou, M. V., Karali, E., Kostaras, E., Mantzaris, M. D., Hatzimichael, E., et al. (2014). Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. ACS Chem. Biol. 9, 2737–2741. doi: 10.1021/cb500259e
Seki, T., Kokuryo, T., Yokoyama, Y., Suzuki, H., Itatsu, K., Nakagawa, A., et al. (2011). Antitumor effects of α-bisabolol against pancreatic cancer. Cancer Sci. 102, 2199–2205. doi: 10.1111/j.1349-7006.2011.02082.x
Shen, Y., Wei, Y., Wang, Z., Jing, Y., He, H., Yuan, J., et al. (2015). TGF-β regulates hepatocellular carcinoma progression by inducing treg cell polarization. Cell. Physiol. Biochem. 35, 1623–1632. doi: 10.1159/000373976
Srivastava, J. K., and Gupta, S. (2007). Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J. Agric. Food Chem. 55, 9470–9478. doi: 10.1021/jf071953k
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., et al. (2015). Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. doi: 10.1016/j.semcancer.2015.03.004. [Epub ahead of print].
Wang, F. M., Galson, D. L., Roodman, G. D., and Ouyang, H. (2011). Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp. Hematol. 39, 999–1006. doi: 10.1016/j.exphem.2011.06.007
Keywords: cancer, bisabolol, therapeutics, apoptosis, leukemia, lymphocytes
Citation: Chirumbolo S (2015) Alpha-bisabolol, not a matter for cancer therapy. Commentary: “Research on the immunosuppressive activity of ingredients contained in sunscreens”. Front. Pharmacol. 6:96. doi: 10.3389/fphar.2015.00096
Received: 03 April 2015; Accepted: 19 April 2015;
Published: 11 May 2015.
Edited by:
Cesare Mancuso, Catholic University School of Medicine, ItalyReviewed by:
Sahdeo Prasad, The University of Texas MD Anderson Cancer Center, USACopyright © 2015 Chirumbolo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Salvatore Chirumbolo, salvatore.chirumbolo@univr.it